Related Experiment Video
Updated: Sep 26, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2
Jie Wang A1, Yufeng Tang2, Jingjing Zhang3
1School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Abstract:
Although it is known that the expression and activity of sirtuin 1 (SIRT1) significantly decrease in doxorubicin (DOX)-induced cardiomyopathy, the role of interaction between SIRT1 and sestrin 2 (SESN2) is largely unknown. In this study, we investigated whether SESN2 could be a crucial target of SIRT1 and the effect of their regulatory interaction and mechanism on DOX-induced cardiac injury. Here, using DOX-treated cardiomyocytes and cardiac-specific Sirt1 knockout mice models, we found SIRT1 deficiency aggravated DOX-induced cardiac structural abnormalities and dysfunction, whereas the activation of SIRT1 by resveratrol (RES) treatment or SIRT1 overexpression possessed cardiac protective effects. Further studies indicated that SIRT1 exerted these beneficial effects by markedly attenuating DOX-induced oxidative damage and apoptosis in a SESN2-dependent manner. Knockdown of Sesn2 impaired RES/SIRT1-mediated protective effects, while upregulation of SESN2 efficiently rescued DOX-induced oxidative damage and apoptosis. Most importantly, SIRT1 activation could reduce DOX-induced SESN2 ubiquitination possibly through reducing the interaction of SESN2 with mouse double minute 2 (MDM2). The recovery of SESN2 stability in DOX-impaired primary cardiomyocytes by SIRT1 was confirmed by Mdm2-siRNA transfection. Taken together, our findings indicate that disrupting the interaction between SESN2 and MDM2 by SIRT1 to reduce the ubiquitination of SESN2 is a novel regulatory mechanism for protecting hearts from DOX-induced cardiotoxicity and suggest that the activation of SIRT1-SESN2 axis has potential as a therapeutic approach to prevent DOX-induced cardiotoxicity.
Insights
Sirtuin 1 (SIRT1) protects against doxorubicin-induced cardiotoxicity by stabilizing sestrin 2 (SESN2). Activating the SIRT1-SESN2 pathway offers a novel therapeutic strategy for preventing heart damage.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biochemistry
Background:
- Doxorubicin (DOX) induces cardiomyopathy, associated with decreased sirtuin 1 (SIRT1) expression.
- The interaction between SIRT1 and sestrin 2 (SESN2) in DOX-induced cardiac injury remains unclear.
Purpose of the Study:
- To investigate SIRT1's role and its regulatory interaction with SESN2 in DOX-induced cardiac injury.
- To elucidate the underlying molecular mechanisms.
Main Methods:
- Utilized DOX-treated cardiomyocytes and cardiac-specific Sirt1 knockout mice models.
- Assessed effects of resveratrol (RES) treatment, SIRT1 overexpression, and Sesn2 knockdown/upregulation.
- Investigated SESN2 ubiquitination and interaction with MDM2.
Main Results:
- SIRT1 deficiency worsened DOX-induced cardiac dysfunction; SIRT1 activation (RES or overexpression) conferred protection.
- SIRT1 protected against DOX-induced oxidative damage and apoptosis via SESN2.
- SIRT1 activation reduced SESN2 ubiquitination by inhibiting the SESN2-MDM2 interaction, stabilizing SESN2.
Conclusions:
- SIRT1 protects the heart from DOX toxicity by reducing SESN2 ubiquitination through the SIRT1-MDM2-SESN2 axis.
- The SIRT1-SESN2 pathway represents a potential therapeutic target for DOX-induced cardiotoxicity.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents

